In the original publication [1], there was a mistake in Figure 7. Results figures from Figure 6D,H have been inserted in Figure 7. The corrected Figure 7 appears below.
Figure 7.
Mito−TIPTP alleviates chronic DSS−induced colitis in mice. (A) Schematic of the chronic colitis model treated 2.5% DSS with Mito−TIPTP (50 ng/kg). (B) The survival of mice was monitored for 9 weeks; mortality was measured for n = 15 mice per group. (C) Weight loss of vehicle or Mito−TIPTP in mice (n = 15). (D) Image (up) and length (down) of colon in 2.5% DSS−induced chronic colitis mice with vehicle or Mito−TIPTP. (E) Representative imaging of H&E staining of the colon (left) (n = 8). Histopathology scores were obtained from H&E staining were determined in 2.5% DSS−induced chronic colitis mice with vehicle or Mito−TIPTP. Scale bar, 100 μm. Statistical significance was determined by Student’s t−test with Bonferroni adjustment (*** p < 0.001) compared with vehicle.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Kim, J.-S.; Kim, Y.-R.; Jang, S.; Wang, S.G.; Cho, E.; Mun, S.-J.; Jeon, H.-I.; Kim, H.-K.; Min, S.-J.; Yang, C.-S. Mito-TIPTP Increases Mitochondrial Function by Repressing the Rubicon-p22phox Interaction in Colitis-Induced Mice. Antioxidants 2021, 10, 1954. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).